Is the FDA contributing to the homelessness crisis?
The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
MedPage Today3d
Clozapine's REMS Program on the Chopping Block at Upcoming FDA Meeting
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
BioSpace1d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Yahoo3d
Opinion - Is the FDA contributing to the homelessness crisis?
the only FDA-approved drug for treatment-resistant schizophrenia, the most severe form of the disorder. The FDA established REMS in 2007 to ensure safety precautions for certain drugs with ...
Yahoo News Australia4d
Opinion - Is the FDA contributing to the homelessness crisis?
The FDA approved clozapine, which is classified as an “atypical” antipsychotic drug, for treatment-resistant schizophrenia in 1990. In 2002, the FDA announced clozapine was effective in ...
Yahoo News Canada3d
Opinion - Is the FDA contributing to the homelessness crisis?
The FDA approved clozapine, which is classified as an “atypical” antipsychotic drug, for treatment-resistant schizophrenia in 1990. In 2002, the FDA announced clozapine was effective in reducing the ...